UroGen Pharma (URGN) Competitors $11.45 +0.29 (+2.60%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends URGN vs. SPPI, PBYI, AKBA, RAPT, MRNS, AVDL, ZYME, SEPN, COGT, and BCAXShould you be buying UroGen Pharma stock or one of its competitors? The main competitors of UroGen Pharma include Spectrum Pharmaceuticals (SPPI), Puma Biotechnology (PBYI), Akebia Therapeutics (AKBA), RAPT Therapeutics (RAPT), Marinus Pharmaceuticals (MRNS), Avadel Pharmaceuticals (AVDL), Zymeworks (ZYME), Septerna (SEPN), Cogent Biosciences (COGT), and Bicara Therapeutics (BCAX). These companies are all part of the "medical" sector. UroGen Pharma vs. Spectrum Pharmaceuticals Puma Biotechnology Akebia Therapeutics RAPT Therapeutics Marinus Pharmaceuticals Avadel Pharmaceuticals Zymeworks Septerna Cogent Biosciences Bicara Therapeutics UroGen Pharma (NASDAQ:URGN) and Spectrum Pharmaceuticals (NASDAQ:SPPI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation, risk and community ranking. Do insiders and institutionals have more ownership in URGN or SPPI? 91.3% of UroGen Pharma shares are held by institutional investors. Comparatively, 21.7% of Spectrum Pharmaceuticals shares are held by institutional investors. 5.1% of UroGen Pharma shares are held by insiders. Comparatively, 2.7% of Spectrum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer URGN or SPPI? In the previous week, Spectrum Pharmaceuticals' average media sentiment score of 0.00 beat UroGen Pharma's score of -0.55 indicating that Spectrum Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment UroGen Pharma Negative Spectrum Pharmaceuticals Neutral Do analysts prefer URGN or SPPI? UroGen Pharma currently has a consensus price target of $48.38, suggesting a potential upside of 322.49%. Given UroGen Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe UroGen Pharma is more favorable than Spectrum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score UroGen Pharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Spectrum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is URGN or SPPI more profitable? Spectrum Pharmaceuticals has a net margin of 0.00% compared to UroGen Pharma's net margin of -129.11%. UroGen Pharma's return on equity of 0.00% beat Spectrum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets UroGen Pharma-129.11% N/A -47.94% Spectrum Pharmaceuticals N/A -218.44%-66.16% Which has more volatility and risk, URGN or SPPI? UroGen Pharma has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Spectrum Pharmaceuticals has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Which has better valuation & earnings, URGN or SPPI? Spectrum Pharmaceuticals has lower revenue, but higher earnings than UroGen Pharma. UroGen Pharma is trading at a lower price-to-earnings ratio than Spectrum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUroGen Pharma$82.71M3.25-$102.24M-$3.15-3.63Spectrum Pharmaceuticals$10.11M20.91-$75.40M-$0.36-2.86 Does the MarketBeat Community prefer URGN or SPPI? Spectrum Pharmaceuticals received 123 more outperform votes than UroGen Pharma when rated by MarketBeat users. However, 73.83% of users gave UroGen Pharma an outperform vote while only 62.28% of users gave Spectrum Pharmaceuticals an outperform vote. CompanyUnderperformOutperformUroGen PharmaOutperform Votes36473.83% Underperform Votes12926.17% Spectrum PharmaceuticalsOutperform Votes48762.28% Underperform Votes29537.72% SummaryUroGen Pharma beats Spectrum Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart URGN vs. The Competition Export to ExcelMetricUroGen PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$261.74M$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E Ratio-3.635.5697.3414.18Price / Sales3.25348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / Book10.507.885.805.12Net Income-$102.24M$153.61M$119.07M$225.99M7 Day Performance-3.46%-2.00%-1.83%-1.32%1 Month Performance-8.55%-7.47%-3.64%0.60%1 Year Performance-9.63%31.80%31.62%26.23% UroGen Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)URGNUroGen Pharma3.78 of 5 stars$11.45+2.6%$48.38+322.5%-7.9%$261.74M$82.71M-3.63200SPPISpectrum PharmaceuticalsN/A$1.03flatN/AN/A$211.41M$10.11M-2.8686PBYIPuma Biotechnology4.4109 of 5 stars$2.84+3.6%$7.00+146.5%-27.0%$134.50M$235.60M5.92185Analyst ForecastPositive NewsAKBAAkebia Therapeutics4.0169 of 5 stars$1.79-1.6%$5.75+221.2%+75.5%$390.54M$194.62M-7.78167RAPTRAPT Therapeutics4.5981 of 5 stars$1.07flat$9.50+787.9%-92.3%$37.40M$1.53M0.0080MRNSMarinus Pharmaceuticals4.4364 of 5 stars$0.31flat$4.79+1,448.8%-95.0%$16.97M$30.99M0.00110Analyst ForecastAnalyst RevisionAVDLAvadel Pharmaceuticals2.3424 of 5 stars$10.75+0.3%$24.43+127.2%-7.5%$1.03B$138.16M-13.61154Short Interest ↓ZYMEZymeworks2.8655 of 5 stars$14.55-1.5%$19.00+30.6%+74.0%$1.02B$76.01M0.00290SEPNSepternaN/A$22.50-7.0%$43.67+94.1%N/A$1.02BN/A0.00N/AAnalyst ForecastNews CoverageGap UpCOGTCogent Biosciences2.866 of 5 stars$9.08+0.2%$14.83+63.4%+20.6%$1.00BN/A0.0080Analyst RevisionBCAXBicara Therapeutics3.1692 of 5 stars$18.38-4.9%$43.33+135.8%N/A$1.00BN/A0.0032Analyst Revision Related Companies and Tools Related Companies Spectrum Pharmaceuticals Competitors Puma Biotechnology Competitors Akebia Therapeutics Competitors RAPT Therapeutics Competitors Marinus Pharmaceuticals Competitors Avadel Pharmaceuticals Competitors Zymeworks Competitors Septerna Competitors Cogent Biosciences Competitors Bicara Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:URGN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free URGN Stock Alerts